High serum miR-421 is associated with metabolic dysregulation and inflammation in patients with metabolic syndrome
High serum miR-421 is associated with metabolic dysregulation and inflammation in patients with metabolic syndrome
复制标题
DOI：
10.2217/epi-2020-0247
复制
发表时间：
2021-03-08
期刊：
影响因子：
3.8
通讯作者：
Hirata, Mario H.
中科院分区：
文献类型：
--
作者：
Braga, Aecio A.;Bortolin, Raul H.;Hirata, Mario H.
目的：探讨代谢综合征（MetS）患者循环中miRNAs与肥胖、代谢状态及炎症标志物的关系。患者和方法：通过定量PCR阵列测量了患有（n = 6）和不患有MetS（n = 6）的患者中372种miRNA的血清水平，并且在更大的队列（MetS，n = 89;非MetS，n = 144）中验证了失调的miRNA。结果：在筛选研究中，7种miRNAs在MetS患者中表达异常，而miR-421在验证研究中仍保持增加。miR-421与MetS、胰岛素抵抗和高血压的高风险相关，并与糖化血红蛋白、三酰甘油、高敏C反应蛋白、IL-6、β-内酰胺酶和脂联素相关（p <0.05）。结论：循环miR-421是代谢综合征（MetS）患者中胰岛素抵抗、代谢失调和炎症状态的潜在生物标志物。Lay abstract本研究旨在探讨代谢综合征（MetS）患者中循环调节小分子（miRNAs）与肥胖、代谢改变和炎症的关系。使用分子生物学技术测量了患有和不患有MetS的患者血清中372种miRNA的水平。在MetS患者中有7种miRNAs发生了改变，其中一种（miR-421）与MetS、胰岛素抵抗和高血压的高风险相关。miR-421还与糖化血红蛋白（用于血糖监测）、血清脂质和炎症分子相关。循环miR-421是MetS患者胰岛素抵抗、代谢失调和炎症状态的潜在生物标志物。
Aim: To explore the association of circulating miRNAs with adiposity, metabolic status and inflammatory biomarkers in patients with metabolic syndrome (MetS). Patients & methods: Serum levels of 372 miRNAs were measured in patients with (n = 6) and without MetS (n = 6) by quantitative PCR array, and dysregulated miRNAs were validated in a larger cohort (MetS, n = 89; non-MetS, n = 144). Results: In the screening study, seven miRNAs were dysregulated in patients with MetS, and miR-421 remained increased in the validation study. miR-421 was associated with a high risk of MetS and insulin resistance and hypertension and correlated with glycated hemoglobin, triacylglycerols, high-sensitivity C-reactive protein, IL-6, resistin and adiponectin (p < 0.05). Conclusion: Circulating miR-421 is a potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.Lay abstractThis study aimed to explore the association of circulating regulatory small molecules (miRNAs) with obesity, metabolic alterations and inflammation in patients with metabolic syndrome (MetS). Levels of 372 miRNAs were measured in blood serum of patients with and without MetS using molecular biology techniques. Seven miRNAs were altered in patients with MetS, and one of them (miR-421) was associated with a high risk of MetS, insulin resistance and hypertension. miR-421 was also correlated with glycated hemoglobin (used for glycemia monitoring), serum lipids and inflammatory molecules. Circulating miR-421 is a small molecule with potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.